TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective Randomized Double Blind Trial to Study the Efficacy of G-CSF and Erythropoetin in Survival of Patients With Decompensated Liver Disease
Brief Summary: Study Design

50 patients will be enrolled and randomized into patients (Group IA) and controls (Group I B)

Investigations:

Hematology CBC, Prothrombin time and INR Peripheral smear, Retics Biochemistry Liver function testing, AFP Kidney function testing Etiology of chronic liver disease Infectious etiology: total antiHBc, anti HCV, HCV RNA, HBV DNA Non infectious etiology: Autoimmune markers, copper studies, iron studies, HOMA IR, FBS Etiology of decompensation Variceal bleed Infection ( blood culture, urine culture, sputum culture, chest xray) Surgery Drugs Alcohol intake Ascitic fluid analysis UGI endoscopy Imaging USG abdomen with Doppler for spleno-portal axis CECT- Triple phase upper abdomen Liver regenerative potential efficacy testing Histology ( by transjugular liver biopsy) Liver Dendritic cells ( CD11c, CD40, CD 54, CD 123, BDCA 2 staining) by flow cytometry CD 34+ cells, CD 45+ cells and CD 133+ cells measurement in hepatic venous blood, peripheral blood and liver biopsy by flow cytometry Markers of proliferation like Ki- 67, proliferating cell nuclear antigen (PCNA) in liver biopsy Markers of angiogenesis like VEGF, v WF in hepatic venous blood Measurement of Hepatic venous pressure gradient ( HVPG)


Options:
A: Arm Label: G-CSF group; Type: ACTIVE_COMPARATOR; Interventions: Drug: Granulocyte Colony Stimulating Factor | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Normal Saline | Intervention Type: DRUG; Name: Granulocyte Colony Stimulating Factor; Assigned to Arm(s): G-CSF group | Intervention Type: DRUG; Name: Normal Saline; Assigned to Arm(s): Placebo
B: Arm Label: G-CSF+EPO; Type: ACTIVE_COMPARATOR; Interventions: Drug: G-CSF+EPO | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: G-CSF+EPO; Assigned to Arm(s): G-CSF+EPO | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: prednisolone or pentoxifylline + pegfiltrastim; Type: EXPERIMENTAL; Interventions: Drug: Standard of care + pegfiltrastim | Arm Label: prednisolone or pentoxifylline; Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard of care | Intervention Type: DRUG; Name: Standard of care + pegfiltrastim; Assigned to Arm(s): prednisolone or pentoxifylline + pegfiltrastim | Intervention Type: DRUG; Name: Standard of care; Assigned to Arm(s): prednisolone or pentoxifylline
D: Arm Label: G-CSF + Standard therapy; Type: EXPERIMENTAL; Interventions: Drug: G-CSF, Other: Standard therapy | Arm Label: Standard therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Standard therapy | Intervention Type: DRUG; Name: G-CSF; Assigned to Arm(s): G-CSF + Standard therapy | Intervention Type: OTHER; Name: Standard therapy; Assigned to Arm(s): G-CSF + Standard therapy, Standard therapy

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Project Fit:a School- and Community-based Intervention to Address Physical Activity and Healthy Eating Among Low-income Elementary School Children
Brief Summary: Project FIT is a collaboration between the public school system, local health systems, physicians, neighborhood associations, businesses, faith-based leaders, community agencies and university researchers to develop a multi-faceted approach to promote physical activity and healthy eating toward the general goal of preventing and reducing childhood obesity among children in Grand Rapids, MI, USA. There are four overall components to Project FIT: school, community, social marketing, and school staff wellness - all that focus on: 1) increasing access to safe and affordable physical activity and nutrition education opportunities in the schools and surrounding neighborhoods; 2) improving the affordability and availability of nutritious food in the neighborhoods surrounding the schools; 3) improving the knowledge, self-efficacy, attitudes and behaviors regarding nutrition and physical activity among school staff, parents and students; 4) impacting the 'culture' of the schools and neighborhoods to incorporate healthful values; and 5) encouraging dialogue among all community partners to leverage existing programs and introduce new ones.


Options:
A: Arm Label: Standard care; Type: EXPERIMENTAL; Interventions: Behavioral: Assertive Community Treatment (ACT) | Intervention Type: BEHAVIORAL; Name: Assertive Community Treatment (ACT); Assigned to Arm(s): Standard care
B: Intervention Type: BEHAVIORAL; Name: In-school Sexual Health Education; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth-friendly health services; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Youth condom promotion & distribution; Assigned to Arm(s): N/A | Intervention Type: BEHAVIORAL; Name: Community activities related to adolescent sexual health; Assigned to Arm(s): N/A
C: Intervention Type: BEHAVIORAL; Name: Program to Encourage Active, Rewarding Lives (PEARL); Assigned to Arm(s): N/A
D: Arm Label: physical activity and nutrition; Type: EXPERIMENTAL; Interventions: Behavioral: Project Fit | Intervention Type: BEHAVIORAL; Name: Project Fit; Assigned to Arm(s): physical activity and nutrition

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: S0927: A Randomized Placebo-Controlled Trial of Omega-3-Fatty Acid for the Control of Aromatase Inhibitor-Induced Musculoskeletal Pain and Stiffness In Women With Early Stage Breast Cancer, Phase III
Brief Summary: RATIONALE: An omega-3 fatty acid-enriched nutritional supplement may help improve muscle and bone pain and stiffness caused by hormone therapy in patients with breast cancer.

PURPOSE: This randomized phase III trial is studying omega-3 fatty acid supplements in treating muscle and bone pain and stiffness in patients with stage I, stage II, or stage III breast cancer receiving hormone therapy.


Options:
A: Arm Label: Tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: tamoxifen citrate | Arm Label: Letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole | Arm Label: Tamoxifen, then letrozole; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Arm Label: Letrozole, then tamoxifen; Type: EXPERIMENTAL; Interventions: Drug: letrozole, Drug: tamoxifen citrate | Intervention Type: DRUG; Name: letrozole; Assigned to Arm(s): Letrozole, Letrozole, then tamoxifen, Tamoxifen, then letrozole | Intervention Type: DRUG; Name: tamoxifen citrate; Assigned to Arm(s): Letrozole, then tamoxifen, Tamoxifen, Tamoxifen, then letrozole
B: Arm Label: Vitamin D3 4000 IU; Type: EXPERIMENTAL; Interventions: Drug: Vitamin D3 | Arm Label: Vitamin D3 600 IU; Type: ACTIVE_COMPARATOR; Interventions: Drug: Vitamin D3 | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 4000 IU | Intervention Type: DRUG; Name: Vitamin D3; Assigned to Arm(s): Vitamin D3 600 IU
C: Arm Label: Arm I; Type: EXPERIMENTAL; Interventions: Dietary Supplement: omega-3 fatty acid | Arm Label: Arm II; Type: PLACEBO_COMPARATOR; Interventions: Other: placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: omega-3 fatty acid; Assigned to Arm(s): Arm I | Intervention Type: OTHER; Name: placebo; Assigned to Arm(s): Arm II
D: Arm Label: All patients; Type: N/A; Interventions: N/A

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study
Brief Summary: To prospectively evaluate in a multicenter open label trial whether the use of zotarolimus-eluting ENDEAVOR Stent implantation in patients at low restenosis or at high bleeding or thrombotic risk will decrease the incidence of 12-month major adverse cardiac events (MACE) including overall death, any myocardial infarction (MI) or any target vessel revascularization (TVR).


Options:
A: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Device: Biolimus eluted from an erodable stent coating (Biomatrix) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: bare-metal stent (Gazelle) | Intervention Type: DEVICE; Name: Biolimus eluted from an erodable stent coating (Biomatrix); Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: bare-metal stent (Gazelle); Assigned to Arm(s): 2
B: Arm Label: bare metal stent; Type: ACTIVE_COMPARATOR; Interventions: Device: Bare metal stent implantation | Arm Label: Endeavor sprint stent; Type: EXPERIMENTAL; Interventions: Device: zotarolimus eluting stent | Intervention Type: DEVICE; Name: Bare metal stent implantation; Assigned to Arm(s): bare metal stent | Intervention Type: DEVICE; Name: zotarolimus eluting stent; Assigned to Arm(s): Endeavor sprint stent
C: Intervention Type: PROCEDURE; Name: Distal protection and drug eluting stent; Assigned to Arm(s): N/A
D: Arm Label: Bare metal stent (BMS); Type: ACTIVE_COMPARATOR; Interventions: Device: bare metal stent prokinetic, chrono, skylor or bluemedical | Arm Label: Drug eluting stent (DES); Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting stent (sirolimus eluting) - CYPHER stent | Arm Label: Abciximab; Type: ACTIVE_COMPARATOR; Interventions: Drug: Abciximab | Arm Label: No abciximab; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Abciximab; Assigned to Arm(s): Abciximab | Intervention Type: DEVICE; Name: bare metal stent prokinetic, chrono, skylor or bluemedical; Assigned to Arm(s): Bare metal stent (BMS) | Intervention Type: DEVICE; Name: drug eluting stent (sirolimus eluting) - CYPHER stent; Assigned to Arm(s): Drug eluting stent (DES)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Sequential Ascending, Repeated-Dose Study of the Safety, Tolerability, and Pharmacokinetics of Subcutaneous REGN668 in Patients With Moderate-to-Severe Atopic Dermatitis
Brief Summary: The purpose of this study is to assess the safety and tolerability of repeated subcutaneous (SC) doses of Dupilumab in participants with moderate-to-severe atopic dermatitis (AD).


Options:
A: Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Other: Background treatment | Arm Label: Dupilumab 150 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Arm Label: Dupilumab 300 mg; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Other: Background treatment | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg | Intervention Type: OTHER; Name: Background treatment; Assigned to Arm(s): Dupilumab 150 mg, Dupilumab 300 mg, Placebo
B: Arm Label: 20 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Arm Label: 30 mg BID; Type: EXPERIMENTAL; Interventions: Drug: Apremilast | Intervention Type: DRUG; Name: Apremilast; Assigned to Arm(s): 20 mg BID, 30 mg BID
C: Arm Label: AN2728 Topical Ointment, 2%; Type: EXPERIMENTAL; Interventions: Drug: AN2728 Topical Ointment, 2% | Arm Label: Matching vehicle control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Matching vehicle control | Intervention Type: DRUG; Name: AN2728 Topical Ointment, 2%; Assigned to Arm(s): AN2728 Topical Ointment, 2% | Intervention Type: DRUG; Name: Matching vehicle control; Assigned to Arm(s): Matching vehicle control
D: Arm Label: Placebo qw; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Arm Label: Dupilumab 300 mg qw; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab | Arm Label: Dupilumab 300 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 200 mg q2w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 300 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Arm Label: Dupilumab 100 mg q4w; Type: EXPERIMENTAL; Interventions: Drug: Dupilumab, Drug: Placebo | Intervention Type: DRUG; Name: Dupilumab; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Dupilumab 300 mg qw | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Dupilumab 100 mg q4w, Dupilumab 200 mg q2w, Dupilumab 300 mg q2w, Dupilumab 300 mg q4w, Placebo qw

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study
Brief Summary: The purpose of our study is to compare the clinical effectiveness and cost-effectiveness of two treatment strategies of Intermittent Claudication (IC) due to an iliac artery obstruction: to start with SUPERvised Exercise Therapy (SET) and deferred Percutaneous Transluminal Angioplasty (PTA) in case of SET failure, or immediate PTA.

It is our hypothesis that PTA as first line treatment is more effective than SET as first line treatment with regard to maximum walking distance, quality of life and costs after one year.


Options:
A: Arm Label: Intervention group: Angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty | Arm Label: Control: Supervised Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised Exercise Therapy | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): Intervention group: Angioplasty | Intervention Type: OTHER; Name: Supervised Exercise Therapy; Assigned to Arm(s): Control: Supervised Exercise Therapy
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised Exercise Therapy, Drug: Cilostazol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Drug: Cilostazol | Arm Label: 3; Type: ACTIVE_COMPARATOR; Interventions: Device: Stent, Behavioral: Supervised Exercise Therapy | Intervention Type: DEVICE; Name: Stent; Assigned to Arm(s): 2, 3 | Intervention Type: BEHAVIORAL; Name: Supervised Exercise Therapy; Assigned to Arm(s): 1, 3 | Intervention Type: DRUG; Name: Cilostazol; Assigned to Arm(s): 1, 2
C: Arm Label: PTA; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty (PTA) | Arm Label: SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Supervised Exercise Programme (SEP) | Arm Label: PTA+SEP; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Combined Treatment | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty (PTA); Assigned to Arm(s): PTA | Intervention Type: PROCEDURE; Name: Supervised Exercise Programme (SEP); Assigned to Arm(s): SEP | Intervention Type: PROCEDURE; Name: Combined Treatment; Assigned to Arm(s): PTA+SEP
D: Arm Label: INVASIVE (INV) group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: INVASIVE (INV) treatment, Other: Best medical treatment (BMT) | Arm Label: NON-INVASIVE (NON) group; Type: ACTIVE_COMPARATOR; Interventions: Other: Best medical treatment (BMT) | Intervention Type: PROCEDURE; Name: INVASIVE (INV) treatment; Assigned to Arm(s): INVASIVE (INV) group | Intervention Type: OTHER; Name: Best medical treatment (BMT); Assigned to Arm(s): INVASIVE (INV) group, NON-INVASIVE (NON) group

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: SUPERvised Exercise Therapy (SET) or Immediate Percutaneous Transluminal Angioplasty (PTA) for Intermittent Claudication (IC) in Patients With an Iliac Artery Obstruction: A Randomized Controlled Trial. SUPER Study
Brief Summary: The purpose of our study is to compare the clinical effectiveness and cost-effectiveness of two treatment strategies of Intermittent Claudication (IC) due to an iliac artery obstruction: to start with SUPERvised Exercise Therapy (SET) and deferred Percutaneous Transluminal Angioplasty (PTA) in case of SET failure, or immediate PTA.

It is our hypothesis that PTA as first line treatment is more effective than SET as first line treatment with regard to maximum walking distance, quality of life and costs after one year.


Options:
A: Arm Label: Best medical treatment; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Supervised exercise training; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Supervised exercise training | Intervention Type: BEHAVIORAL; Name: Supervised exercise training; Assigned to Arm(s): Supervised exercise training
B: Intervention Type: PROCEDURE; Name: Exercise therapy; Assigned to Arm(s): N/A | Intervention Type: DEVICE; Name: Accelerometer (PAM; Personal Activity Monitor); Assigned to Arm(s): N/A | Intervention Type: PROCEDURE; Name: Oral Exercise Therapy advise; Assigned to Arm(s): N/A
C: Arm Label: Angioplasty / surgery and exercise therapy; Type: EXPERIMENTAL; Interventions: Procedure: Angioplasty / surgery and exercise therapy | Arm Label: Angioplasty / surgery; Type: NO_INTERVENTION; Interventions: Procedure: angioplasty / surgery | Intervention Type: PROCEDURE; Name: angioplasty / surgery; Assigned to Arm(s): Angioplasty / surgery | Intervention Type: PROCEDURE; Name: Angioplasty / surgery and exercise therapy; Assigned to Arm(s): Angioplasty / surgery and exercise therapy
D: Arm Label: Intervention group: Angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Percutaneous Transluminal Angioplasty | Arm Label: Control: Supervised Exercise Therapy; Type: ACTIVE_COMPARATOR; Interventions: Other: Supervised Exercise Therapy | Intervention Type: PROCEDURE; Name: Percutaneous Transluminal Angioplasty; Assigned to Arm(s): Intervention group: Angioplasty | Intervention Type: OTHER; Name: Supervised Exercise Therapy; Assigned to Arm(s): Control: Supervised Exercise Therapy

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evidence Based Decision Making: Integrating Clinical Prediction Rules Into Electronic Health Records
Brief Summary: Clinical prediction rules (CPRs) are frontline decision aids that help physicians make evidence-based, cost-effective decisions that benefit their patients. The aims of this project are to incorporate two well validated CPRs (Streptococcal Pharyngitis Prediction Rule and the Pneumonia Clinical Prediction Rule) into an outpatient Electronic Medical Record System (EMR) and to perform a randomized controlled trial of the effectiveness of integrated CPRs impact on doctor's behaviors (e.g. test ordering and medication prescribing).


Options:
A: Arm Label: iCPR randomized providers; Type: EXPERIMENTAL; Interventions: Other: Integrated Clinical Prediction Rule (iCPR) | Arm Label: Control providers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated Clinical Prediction Rule (iCPR); Assigned to Arm(s): iCPR randomized providers
B: Arm Label: Family Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support | Arm Label: Clinical Decision Support; Type: EXPERIMENTAL; Interventions: Behavioral: Clinician Decision Support | Arm Label: Family DS+ Clinician DS; Type: EXPERIMENTAL; Interventions: Behavioral: Family Decision Support, Behavioral: Clinician Decision Support, Other: Family Decision Support and Clinician Decision Support | Arm Label: Control; Type: OTHER; Interventions: Other: Control | Intervention Type: BEHAVIORAL; Name: Family Decision Support; Assigned to Arm(s): Family DS+ Clinician DS, Family Decision Support | Intervention Type: BEHAVIORAL; Name: Clinician Decision Support; Assigned to Arm(s): Clinical Decision Support, Family DS+ Clinician DS | Intervention Type: OTHER; Name: Family Decision Support and Clinician Decision Support; Assigned to Arm(s): Family DS+ Clinician DS | Intervention Type: OTHER; Name: Control; Assigned to Arm(s): Control
C: Arm Label: Trained Clinicians; Type: EXPERIMENTAL; Interventions: Behavioral: Training | Arm Label: Non-trained Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Non-volunteer Clinicians; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Training; Assigned to Arm(s): Trained Clinicians
D: Arm Label: Academic Detailing (AD); Type: NO_INTERVENTION; Interventions: N/A | Arm Label: AD + Integrated Tobacco Order Set; Type: EXPERIMENTAL; Interventions: Other: AD + Integrated Tobacco Order Set | Intervention Type: OTHER; Name: AD + Integrated Tobacco Order Set; Assigned to Arm(s): AD + Integrated Tobacco Order Set

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Evidence Based Decision Making: Integrating Clinical Prediction Rules Into Electronic Health Records
Brief Summary: Clinical prediction rules (CPRs) are frontline decision aids that help physicians make evidence-based, cost-effective decisions that benefit their patients. The aims of this project are to incorporate two well validated CPRs (Streptococcal Pharyngitis Prediction Rule and the Pneumonia Clinical Prediction Rule) into an outpatient Electronic Medical Record System (EMR) and to perform a randomized controlled trial of the effectiveness of integrated CPRs impact on doctor's behaviors (e.g. test ordering and medication prescribing).


Options:
A: Arm Label: Intervention; Type: OTHER; Interventions: Behavioral: Vascular Management Program, Behavioral: Clinical Care Coordinators, Behavioral: Web-based Vascular Tracker for Patient and Physician, Behavioral: Automated Telephone Reminder System | Intervention Type: BEHAVIORAL; Name: Vascular Management Program; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Clinical Care Coordinators; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Web-based Vascular Tracker for Patient and Physician; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Automated Telephone Reminder System; Assigned to Arm(s): Intervention
B: Arm Label: Receive CDS intervention; Type: EXPERIMENTAL; Interventions: Other: MAPLE | Arm Label: No CDS intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: MAPLE; Assigned to Arm(s): Receive CDS intervention
C: Arm Label: iCPR randomized providers; Type: EXPERIMENTAL; Interventions: Other: Integrated Clinical Prediction Rule (iCPR) | Arm Label: Control providers; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Integrated Clinical Prediction Rule (iCPR); Assigned to Arm(s): iCPR randomized providers
D: Arm Label: e-POCT; Type: EXPERIMENTAL; Interventions: Other: Management of febrile children using e-POCT | Arm Label: ALMANACH; Type: ACTIVE_COMPARATOR; Interventions: Other: Management of febrile children using ALMANACH | Arm Label: Routine practice; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Management of febrile children using e-POCT; Assigned to Arm(s): e-POCT | Intervention Type: OTHER; Name: Management of febrile children using ALMANACH; Assigned to Arm(s): ALMANACH

Answer: C